LncRNA PGM5-AS1 Impairs the Resistance of Cervical Cancer to Cisplatin by Regulating the Hippo and PI3K-AKT Pathways

Overview

Journal Biochem Genet

Specialty Molecular Biology

Date 2024 Dec 29

PMID 39733221

Authors

Huimin Wang

Yi Yang

Enjing Zhang

Dan Wang

Weiqiong Cai

Chun Li

Qiong Wei

Affiliations

Soon will be listed here.

Abstract

Cisplatin, a platinum-based chemotherapeutic agent, can be used to treat cervical cancer (CC), but cisplatin resistance is increased during the cisplatin treatment. Long non-coding RNA PGM5-AS1 reportedly participates in CC tumorigenesis; however, its role in CC patients with cisplatin resistance has not been revealed. The present aimed to examine the role of PGM5-AS1 in modulating cisplatin resistance in CC. The PGM5-AS1 expression in CC tissues from 29 patients was quantified using quantitative reverse transcription-polymerase chain reaction. The cisplatin-resistant CC cells were constructed by using increasing cisplatin concentrations. The effects of cisplatin resistance interacting with PGM5-AS1 on CC cell malignancy were confirmed by performing Cell Counting Kit 8, colony formation, wound healing, and transwell assays. The key proteins of the Hippo and PI3K-AKT signaling pathways were evaluated by Western blotting. PGM5-AS1 with low expression in CC tissues was correlated to higher International Federation of Gynecology and Obstetrics stage, poor differentiation, lymph node metastasis, and cisplatin resistance. PGM5-AS1 overexpression suppressed the proliferation, migration, and invasion abilities of cisplatin-resistant CC cells. Additionally, PGM5-AS1 overexpression in cisplatin-resistant CC cells could induce the activation of the Hippo signaling pathway and the inactivation of the PI3K-AKT signaling pathway. PGM5-AS1 enhanced the CC cell's sensitivity to cisplatin by activating the Hippo signaling pathway and inactivating the PI3K-AKT signaling pathway. Our study data may provide a novel therapeutic biomarker to overcome cisplatin resistance in CC treatment.

Citing Articles

JAK/STAT signaling as a key regulator of ferroptosis: mechanisms and therapeutic potentials in cancer and diseases.

Dai Y, Cui C, Jiao D, Zhu X Cancer Cell Int. 2025; 25(1):83.

PMID: 40055704 PMC: 11889932. DOI: 10.1186/s12935-025-03681-6.

Long noncoding RNA SNHG4 promotes glioma progression via regulating miR-367-3p/MYO1B axis in zebrafish xenografts.

Zhang Y, Wang Y, Yang Y, Sun C Hum Cell. 2025; 38(2):53.

PMID: 39951205 PMC: 11828807. DOI: 10.1007/s13577-025-01183-1.

References

Bahrami A, Hasanzadeh M, Hassanian S, Shahidsales S, Ghayour-Mobarhan M, Ferns G . The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy. J Cell Biochem. 2017; 118(12):4163-4169. DOI: 10.1002/jcb.26118. View

Bhattacharjee R, Dey T, Kumar L, Kar S, Sarkar R, Ghorai M . Cellular landscaping of cisplatin resistance in cervical cancer. Biomed Pharmacother. 2022; 153:113345. DOI: 10.1016/j.biopha.2022.113345. View

Bi L, Ma F, Tian R, Zhou Y, Lan W, Song Q . AJUBA increases the cisplatin resistance through hippo pathway in cervical cancer. Gene. 2017; 644:148-154. DOI: 10.1016/j.gene.2017.11.017. View

Buranjiang G, Abuduwanke A, Li X, Abulizi G . LncRNA HOTAIR enhances RCC2 to accelerate cervical cancer progression by sponging miR-331-3p. Clin Transl Oncol. 2023; 25(6):1650-1660. DOI: 10.1007/s12094-022-03059-4. View

Burmeister C, Khan S, Schafer G, Mbatani N, Adams T, Moodley J . Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 2022; 13:200238. PMC: 9062473. DOI: 10.1016/j.tvr.2022.200238. View

Chen R, Fang T, Liu N, Shi X, Wang J, Yu H . Transglutaminase 3 suppresses proliferation and cisplatin resistance of cervical cancer cells by inactivation of the PI3K/AKT pathway. Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(4):2269-2280. DOI: 10.1007/s00210-023-02757-2. View

Du L, Gao Y . PGM5-AS1 impairs miR-587-mediated GDF10 inhibition and abrogates progression of prostate cancer. J Transl Med. 2021; 19(1):12. PMC: 7789719. DOI: 10.1186/s12967-020-02572-w. View

Du Y, Geng G, Zhao C, Gao T, Wei B . LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis. BMC Cancer. 2022; 22(1):1145. PMC: 9641762. DOI: 10.1186/s12885-022-10188-0. View

Duan W, Liu X . PSAT1 Upregulation Contributes to Cell Growth and Cisplatin Resistance in Cervical Cancer Cells via Regulating PI3K/AKT Signaling Pathway. Ann Clin Lab Sci. 2020; 50(4):512-518. View

10.

Duan X, Wang L, Wang Z, Wei W, Wang M, Ding D . LncRNA PGM5-AS1 Inhibits the Progression of Bladder Cancer by Regulating miR-587/SLIT3 Axis. Crit Rev Eukaryot Gene Expr. 2022; 32(8):9-22. DOI: 10.1615/CritRevEukaryotGeneExpr.2022042376. View

11.

Fu M, Hu Y, Lan T, Guan K, Luo T, Luo M . The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022; 7(1):376. PMC: 9643504. DOI: 10.1038/s41392-022-01191-9. View

12.

Hou H, Yu R, Zhao H, Yang H, Hu Y, Hu Y . LncRNA OTUD6B-AS1 Induces Cisplatin Resistance in Cervical Cancer Cells Through Up-Regulating Cyclin D2 miR-206. Front Oncol. 2021; 11:777220. PMC: 8569895. DOI: 10.3389/fonc.2021.777220. View

13.

Johnson C, James D, Marzan A, Armaos M . Cervical Cancer: An Overview of Pathophysiology and Management. Semin Oncol Nurs. 2019; 35(2):166-174. DOI: 10.1016/j.soncn.2019.02.003. View

14.

Sarapultsev A, Vassiliev P, Grinchii D, Kiss A, Mach M, Osacka J . Combined In Silico, Ex Vivo, and In Vivo Assessment of L-17, a Thiadiazine Derivative with Putative Neuro- and Cardioprotective and Antidepressant Effects. Int J Mol Sci. 2021; 22(24). PMC: 8708481. DOI: 10.3390/ijms222413626. View

15.

Liu K, Gao L, Ma X, Huang J, Chen J, Zeng L . Long non-coding RNAs regulate drug resistance in cancer. Mol Cancer. 2020; 19(1):54. PMC: 7066752. DOI: 10.1186/s12943-020-01162-0. View

16.

Liu W, Liu P, Gao H, Wang X, Yan M . Long non-coding RNA PGM5-AS1 promotes epithelial-mesenchymal transition, invasion and metastasis of osteosarcoma cells by impairing miR-140-5p-mediated FBN1 inhibition. Mol Oncol. 2020; 14(10):2660-2677. PMC: 7530781. DOI: 10.1002/1878-0261.12711. View

17.

Liu Y, Guo R, Qiao Y, Han L, Liu M . LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis. Cancer Cell Int. 2020; 20:190. PMC: 7247171. DOI: 10.1186/s12935-020-01278-9. View

18.

Luo X, Wei J, Yang F, Pang X, Shi F, Wei Y . Exosomal lncRNA HNF1A-AS1 affects cisplatin resistance in cervical cancer cells through regulating microRNA-34b/TUFT1 axis. Cancer Cell Int. 2019; 19:323. PMC: 6889431. DOI: 10.1186/s12935-019-1042-4. View

19.

Mei X, Xiong J, Liu J, Huang A, Zhu D, Huang Y . DHCR7 promotes lymph node metastasis in cervical cancer through cholesterol reprogramming-mediated activation of the KANK4/PI3K/AKT axis and VEGF-C secretion. Cancer Lett. 2024; 584:216609. DOI: 10.1016/j.canlet.2024.216609. View

20.

Najafi S, Khatami S, Khorsand M, Jamali Z, Shabaninejad Z, Moazamfard M . Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Exp Cell Res. 2022; 418(2):113294. DOI: 10.1016/j.yexcr.2022.113294. View